H
Hotgen Biotech
Chemiluminescence and UPT POCT IVD analyzers and reagents
About Hotgen Biotech
Beijing Hotgen Biotech Co., Ltd. (STAR Market 688068) develops chemiluminescence and up-converting phosphor POCT analyzers plus accompanying immunoassay reagents for hospitals and labs. Founded in 2005 and headquartered in Beijing Daxing Biomedical Base, Hotgen's menu covers thyroid, reproductive hormones, cardiac, inflammation, oncology and related assays, with CE/IVDR registrations and growing export channels across Europe, India and the Americas.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2005
- Headquarters
- China
- Listing
- IPO 2019
- Sector
- Hard Tech
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- SGShenZhen GTJA Investment Group
Series B and later1 investor entered at this stage
- SGShenZhen GTJA Investment Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hotgen Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hotgen Biotech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.